Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
8
×
boston blog main
boston top stories
life sciences
national blog main
alnylam pharmaceuticals
national top stories
rna interference
clinical trials
drugs
new york blog main
san francisco blog main
biotech
deals
fda
new york top stories
patisiran
san francisco top stories
akcea therapeutics
aminolevulinic acid
barry greene
boehringer ingelheim
dan ollendorf
eli lilly
givosiran
harvard pilgrim health care
hereditary transthyretin amyloidosis
inotersen
institute for clinical and economic review
onpattro
san diego blog main
san diego top stories
sanofi
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
What
rna
8
×
interference
medicine
alnylam
fda
rnai
second
ago
deal
drug
gene
medicines
approval
companies
historic
market
new
pharmaceuticals
seek
speedy
therapy
time
uses
abandoning
approve
approves
aren’t
awaits
baggage
bets
betting
billion
bio
biological
biopharma
cancer
car
cells
cleared
comes
Language
unset
Current search:
boston
×
rna
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”